This study shows that lowering MARK4 levels reduces pathological tau aggregates and astrogliosis and ameliorates neurodegeneration and behavioural deficits in a mouse model of tauopathy, suggesting MARK4's critical role in disease pathogenesis. Here, MAPT is linked to tauopathy.